No profile data available.
Siga Technologies, Inc. (SIGA) is a healthcare company in the antiviral pharmaceuticals industry, based in New York, United States, with about 49 full-time employees.
It reported revenue of $138.72 million for fiscal year 2024, down 0.9% from fiscal year 2023, and net income of $59.21 million. In Q3 2025 (the quarter ended September 30, 2025) revenue was $2.62 million, down 73.8% from a year before. United States was its largest region in fiscal year 2025, with 94% of revenue. Its market capitalization was $235.67 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 9, 2026.
, a commercial-stage pharmaceutical company, focuses on the health security market in the United States. The company's lead product is TPOXX, an antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. was incorporated in 1995 and is headquartered in New York, New York.
Siga Technologies reported $138.72 million in revenue for fiscal year 2024, down 0.9% from $139.92 million in fiscal year 2023. In Q3 2025 revenue was $2.62 million.
United States: 94% of revenue by region in fiscal year 2025, followed by Canada (6%).
$235.67 million as of October 9, 2026.
Listed companies of a similar size in the same industry (antiviral pharmaceuticals) include Agenus Inc. (AGEN), SAB Biotherapeutics, Inc. (SABS), InflaRx N.v. (IFRX), Invivyd, Inc. (IVVD).